IAS 2017 Comp Review



About the Program

Program Overview

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 9th IAS Conference on HIV Science (IAS 2017). This program consists of five components: (1) IAS 2017 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) European Perspective on IAS 2017**: a 1.5 hour Case-based Internet symposium featuring Europe based expert faculty reviewing and discussing key presentations with a focus on clinical management and treatment in the EU; (3) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (4) Rapid-Fire Review of IAS 2017: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (5) From Conference to Clinic: Reviewing and Applying Data From IAS 2017: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care. 

The Comprehensive Expert Review and Discussion of Key Presentations part of the program will feature HIV experts reviewing and discussing the most important studies on HIV therapy presented at IAS 2017. This review and discussion will provide a comprehensive overview of each of the posters and presentations selected. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from IAS 2017 and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

All online components of the program will be accessible at www.viraled.com.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at IAS 2017 and it is not sanctioned by the organizers of IAS 2017.

 ** The European Perspective on IAS 2017 component is jointly provided by the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc. in collaboration with Postgraduate Institute for Medicine and supported by an independent educational grant from ViiV Healthcare.  

Back to Top  

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top  

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use data reported at IAS 2017 for counseling, testing and antiretroviral treatment to prevent HIV infection, especially in underserved communities

  • Use in a clinical setting findings from key studies on HIV/AIDS diagnosis, management, and treatment presented at IAS 2017

  • Employ strategies based on studies and data presented at IAS 2017 for helping HIV-positive patients in medically underserved communities link to and stay in appropriate and effective HIV care

  • Discuss with patients and colleagues the studies and data on therapies for HIV/AIDS presented at IAS 2017 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS

Release Date: August 4, 2017

Expiration Date: August 4, 2018

Estimated time to complete each Poster/Presentation: 15-45 minutes 

Media: Internet


Back to Top  



José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain  

Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom

Marta Boffito, MD, PhD
St. Stephen's AIDS Trust and Imperial College
Chelsea & Westminster Hospital
London, United Kingdom

Jürgen Rockstroh, MD
Professor of Medicine 
Department of Medicine I
University Hospital
Bonn, Germany

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine 
at the University of Pennsylvania
Philadelphia, Pennsylvania

Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health,
University of Chicago
Chicago, Illinois

Jean-Michel Molina, MD, PhD
Head, Infectious Diseases Department
Hospital Saint-Louis
London, United Kingdom


Back to Top  

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Jose Arribas, MD

  • Consulting Fees: Merck, Gilead
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: ViiV, Janssen, Abbvie, BMS,Gilead, MSD 

Ian Frank, MD 

  • Consulting Fees: Gilead
  • Contracted Research: ViiV/GSK

Jean-Michel Molina, MD, PhD

  • Consulting Fees: Gilead, ViiV, Merck, BMS
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Gilead
  • Contracted Research: Gilead
Graeme Moyle, MD


  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: BMS, Gilead, Merck, Tobira/Allergen, Teva, Mylan

Juergen Rockstroh, MD

  • Consulting Fees: Abbott, Abbvie, Gilead, Janssen, Merck, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Abbot, Gilead, Merck
  • Contracted Research: Gilead

Paul Sax, MD

  • Consulting Fees: Abbvie, BMS, GSK/ViiV, Gilead, Janssen, Merck
  • Contracted Research: Gilead, BMS, GSK/ViiV

Renslow Sherer, MD

  • Consulting Fees: Gilead

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The PIM planners and managers, Trace Hutchison, PharmD,  Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan Shultz, MSN, RN, CHCP have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc., and Gilead Sciences Medical Affairs. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc., and Gilead Sciences Medical Affairs. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Poster/Presentation Listing


Superior efficacy of DTG plus 2 NRTIs compared with LPV/RTV plus 2 NRTIs in second-line treatment: interim data from the DAWNING study


Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum


The EMERALD study


The EXPEDITION-2 and ENDURANCE-1 studies


Weekly oral MK-8591 protects male rhesus macaques against repeated low dose intrarectal challenege with SHIVC109P3


Switching from TDF/FTC/EFV to TDF/FTC/RPV in virologically suppressed HIV+ individuals without perceived neuropsychiatric complaints improves CNS associated symptoms

 IAS_17_CompReview_Abstract_buttons_MOAB0105LB.jpg A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48

Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.    


This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at IAS 2017 and it is not sanctioned by the organizers of IAS 2017.

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs. 

Prepare to print

Share this page:

Get link code to this page     

Back to Top